- Home
- NRGV vs CRDF Comparison
NRGV vs CRDF Comparison
Compare NRGV & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRGV
- CRDF
- Stock Information
- Founded
- NRGV 2017
- CRDF 1999
- Country
- NRGV United States
- CRDF United States
- Employees
- NRGV N/A
- CRDF N/A
- Industry
- NRGV Industrial Machinery/Components
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NRGV Miscellaneous
- CRDF Health Care
- Exchange
- NRGV Nasdaq
- CRDF Nasdaq
- Market Cap
- NRGV 133.4M
- CRDF 144.4M
- IPO Year
- NRGV N/A
- CRDF N/A
- Fundamental
- Price
- NRGV $2.29
- CRDF $2.05
- Analyst Decision
- NRGV Buy
- CRDF Strong Buy
- Analyst Count
- NRGV 3
- CRDF 5
- Target Price
- NRGV $1.58
- CRDF $11.10
- AVG Volume (30 Days)
- NRGV 2.0M
- CRDF 1.1M
- Earning Date
- NRGV 11-11-2025
- CRDF 11-06-2025
- Dividend Yield
- NRGV N/A
- CRDF N/A
- EPS Growth
- NRGV N/A
- CRDF N/A
- EPS
- NRGV N/A
- CRDF N/A
- Revenue
- NRGV $51,716,000.00
- CRDF $545,000.00
- Revenue This Year
- NRGV $314.58
- CRDF N/A
- Revenue Next Year
- NRGV $39.00
- CRDF N/A
- P/E Ratio
- NRGV N/A
- CRDF N/A
- Revenue Growth
- NRGV N/A
- CRDF N/A
- 52 Week Low
- NRGV $0.60
- CRDF $1.90
- 52 Week High
- NRGV $2.70
- CRDF $5.64
- Technical
- Relative Strength Index (RSI)
- NRGV 70.49
- CRDF 36.50
- Support Level
- NRGV $1.73
- CRDF $2.03
- Resistance Level
- NRGV $2.33
- CRDF $2.27
- Average True Range (ATR)
- NRGV 0.18
- CRDF 0.12
- MACD
- NRGV 0.00
- CRDF 0.04
- Stochastic Oscillator
- NRGV 94.12
- CRDF 31.91
About NRGV Energy Vault Holdings Inc.
Energy Vault Holdings Inc is a grid-scale energy storage company that is driving a faster transition to renewable power by solving the intermittence issues that are inherent to the prevalent sources of renewable energy, solar and wind. Geographical presence in United States, China and Other. Majority of its revenue comes from U.S.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.